Defining prognostic subgroups and treatment outcomes in estrogen receptor low-positive de novo metastatic breast cancer

Key Points

• This research aims to identify prognostic subgroups and evaluate treatment outcomes for estrogen receptor low-positive metastatic breast cancer patients.
• Analyze survival data based on PR-positivity among ER low-positive patients and ER-negative patients.
• Evaluate the suitability of first-line endocrine therapy in ER low-positive patients.
• PR-positivity correlates with improved survival for ER low-positive patients compared to ER-negative patients.
• Endocrine therapy shows promise as a viable first-line treatment for ER low-positive metastatic cases.